Drug
Int 747
Int 747: highest development phase Phase 2, developed by Intercept Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Intercept Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| INT-747 NCT00501592 | Phase 2 | Diabetes Mellitus, Type II |
| INT-747 NCT00550862 | Phase 2 | Liver Cirrhosis, Biliary |
Latest
No recent events.
Follow Int 747 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.